ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.000
-0.030 (-1.48%)
May 18, 2026, 10:48 AM EDT - Market open
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
269.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 157.08M |
| Niagen Bioscience | 130.42M |
| Compugen | 72.76M |
| Editas Medicine | 38.69M |
| Zentalis Pharmaceuticals | 26.87M |
| AC Immune | 4.62M |
| Silence Therapeutics | 839.00K |
| SAB Biotherapeutics | 114.70K |
ALXO News
- 10 days ago - ALX Oncology Holdings Earnings Call Transcript: Q1 2026 - Transcripts
- 10 days ago - ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 days ago - ALX Oncology evorpacept combination data presented at ESMO congress - TheFly
- 11 days ago - ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - GlobeNewsWire
- 18 days ago - ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 - GlobeNewsWire
- 4 weeks ago - ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 5 weeks ago - ALX Oncology appoints Jeff Knight as chief development, operating officer - TheFly
- 5 weeks ago - ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - GlobeNewsWire